This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shire US, Inc.
Shire US, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1986, the company has achieved significant milestones, including its focus on developing innovative therapies for rare diseases and specialty conditions. Shire is renowned for its core products, particularly in the fields of ophthalmology and rare genetic disorders, with Xiidra being a notable treatment for dry eye disease. The company’s commitment to patient-centric solutions and cutting-edge research distinguishes it in a competitive market. With a strong market position, Shire has garnered recognition for its contributions to improving patient outcomes and advancing healthcare solutions globally.
DitchCarbon Score
How does Shire US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire US, Inc.'s score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire US, Inc. currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with Takeda Pharmaceutical Company Limited, from which it inherits climate commitments and initiatives. Shire US, Inc. follows the sustainability and climate strategies set by Takeda, which include various reduction initiatives and targets. These initiatives are cascaded down from Takeda, reflecting a commitment to addressing climate change at multiple levels within the organisation. While specific reduction targets for Shire US, Inc. are not detailed, the overarching goals from Takeda include adherence to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These commitments indicate a proactive approach to managing and reducing carbon emissions across their operations. In summary, while Shire US, Inc. does not provide specific emissions data, it aligns with the climate commitments and reduction strategies established by its parent company, Takeda Pharmaceutical Company Limited, demonstrating a commitment to sustainability and climate action within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shire US, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
